By targeting underlying synovitis, the novel intra-articular liraglutide formulation 4P004 aims to bridge the gap between transient symptom relief and disease modification in knee OA.

The Phase 2b trial has been designed to be statistically powered to evaluate key efficacy endpoints, including change from baseline in pain and physical function compared with placebo, measured at ...

We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Enlivex Ltd. is one of the oversold stocksto ...

Research presented at WCO suggests hyaluronic acid injections provide modest but consistent pain relief in knee ...

Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report ...

Ongoing research led by Professor Martyn Snow, a Consultant Orthopaedic Surgeon at The Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry, Shropshire, explores how Arthrosamid (R) could ...

A single shot into a damaged joint reversed osteoarthritis in animals within weeks, according to researchers at the ...

A growing cluster of laboratory and early clinical studies is testing whether injectable hydrogels, slow-release drug depots, ...

Total Knee Replacement Market OverviewThe global total knee replacement (TKR) market is projected to witness steady growth over the next five years with an estimated growth rate of around 5%. The ...

Knee osteoarthritis (KOA) is a prevalent degenerative joint disease worldwide. Current treatments primarily offer only symptomatic relief and lack disease-modifying efficacy. Photobiomodulation ...

In patients with knee osteoarthritis, physical function improved more with intra-articular injections combined with exercise than with exercise alone in the long-term. Combining structured exercise ...